Skip to main content
×
Home
    • Aa
    • Aa

A comparison of hepatitis B seroepidemiology in ten European countries

  • A. NARDONE (a1), C. G. ANASTASSOPOULOU (a2), H. THEETEN (a3), B. KRIZ (a4), I. DAVIDKIN (a5), W. THIERFELDER (a6), D. O'FLANAGAN (a7), B. BRUZZONE (a8), J. MOSSONG (a9), H. J. BOOT (a10), D. BUTUR (a11), M. SLAČIKOVÁ (a12), M. L. C. PANAIT (a11), W. HELLENBRAND (a6), H. DE MELKER (a10), Z. SOBOTOVÁ (a12), G. ICARDI (a8), N. ANDREWS (a1), R. G. PEBODY (a1), P. VAN DAMME (a3), G. KAFATOS (a1), E. MILLER (a1) and A. HATZAKIS (a2)...
Abstract
SUMMARY

To inform current and future vaccination strategies, we describe the seroepidemiology of hepatitis B virus (HBV) infection in ten representative European countries using standardized serology that allowed international comparisons. Between 1996 and 2003, national serum banks were compiled by collecting residual sera or by community sampling; sera were then tested by each country using its preferred enzyme immunoassays and testing algorithm, and assay results were standardized. Information on current and past HBV vaccination programmes in each country was also collected. Of the ten countries, six reported low levels (<3%) of antibodies against HBV core antigen (anti-HBc). Of the eight countries testing for HBV surface antigen (HBsAg), the highest prevalence was reported in Romania (5·6%) and in the remaining seven countries prevalence was <1%. Universal HBV vaccination programmes had been established in seven countries as recommended by the World Health Organization, but the seroprevalence of antibodies against HBsAg (anti-HBs) was lower than the reported vaccine coverage in three countries. Regular serological surveys to ascertain HBV status within a population, such as reported here, provide important data to assess the need for and to evaluate universal HBV vaccination programmes.

Copyright
Corresponding author
*Author for correspondence: Dr A. Nardone, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, LondonNW9 5EQ, UK. (Email: anthony.nardone@hpa.org.uk)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2. C Roure . Overview of epidemiology and disease burden of hepatitis B in the European region. Vaccine 1995; 13: S1821.

4. P van Damme , A Vorsters . Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. Journal of Medical Virology 2002; 67: 433439.

9. T O'Connell , Prevalence of hepatitis B anti-core antibody in the Republic of Ireland. Epidemiology and Infection 2000; 125: 701704.

11. S Hahne , Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: implications for immunisation policy. Journal of Clinical Virology 2004; 29: 211220.

15. NJ Andrews , The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiology and Infection 2000; 125: 127141.

16. G Kafatos , N Andrews , A Nardone . Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine 2005; 23: 50225027.

17. A Dominguez , Changes in the sero-epidemiology of hepatitis B infection in Catalonia, 1989–1996. Vaccine 2000; 18: 23452350.

18. G Da Villa , Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007; 25: 31333136.

19. W Jilg , M Schmidt , F Deinhardt . Vaccination against hepatitis B: comparison of three different vaccination schedules. Journal of Infectious Diseases 1989; 160: 766769.

20. M Gesemann , N Scheiermann . Hepatitis B vaccine boosting among young healthy adults. Lancet 1995; 345: 395396.

21. DJ West , GB Calandra . Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 10191027.

23.European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561565.

25. D FitzSimons , Prevention and control of viral hepatitis through adolescent health programmes in Europe. Vaccine 2007; 25: 86518659.

26. A Mele , T Stroffolini , AR Zanetti . Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. Journal of Medical Virology 2002; 67: 440443.

28. J Zuckerman , Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe? Lancet Infectious Diseases 2007; 7: 410419.

30. J Banatvala , P Van Damme , N Emiroglu . Hepatitis B immunisation in Britain: time to change? British Medical Journal 2006; 332: 804805.

31. W Thierfelder , Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. European Journal of Epidemiology 2001; 17: 429435.

32. RT Gandhi , Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. Journal of Infectious Diseases 2005; 191: 14351441.

35. A Nardone , The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 2007; 25: 78667872.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 3
Total number of PDF views: 11 *
Loading metrics...

Abstract views

Total abstract views: 121 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 23rd May 2017. This data will be updated every 24 hours.